Following on from information provided to NICE by the company in July 2022, the appraisal of Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Decision | Selected |
| Process | TA |
| ID number | 3829 |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 July 2023 | Discontinued. Following on from information provided to NICE by the company in July 2022, the appraisal of Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 01 July 2022 | Suspended. For information, the company have announced that the trial did not meet its primary endpoint of overall survival (OS) in patients whose tumour cells express PD-L1 ≥1% and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual